KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) Stock

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) is a Healthcare stock trading at $27.20 (as of 2026-08-20), with a market capitalization of $1.59B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.

Understand KESTRA MEDICAL TECHNOLOGIES, LTD.: how it makes money

Kestra Medical Technologies develops and commercializes the Cardiac Recovery System platform, built around the ASSURE wearable cardioverter defibrillator (WCD), integrating monitoring, therapeutic treatment, digital health, and patient support to generate sales activity driven by prescriptions for the ASSURE system.

Profit growth depends on converting demand, measured by ASSURE system prescriptions and prescriptions generated, into actual system utilization through conversion and fitting performance, which then affects operational efficiency through metrics like cost per fit decrease and the share of fittings with in-network benefits.

Business quality (Weak): The company has strong operating activity indicators for its ASSURE program (such as prescriptions and wear-time use), but profitability is currently weak, with an operating margin of -141.6% despite a 52.6% gross margin.

Bull case

  • Integrated solution approach: The Cardiac Recovery System platform combines monitoring, therapeutic treatment, digital health, and patient support services into one unified offering centered on the ASSURE WCD.
  • Coverage and distribution footprint: The company tracks Health Plan Members Covered for the ASSURE System and Active Sales Territories, indicating an established distribution and payer coverage effort.
  • Measured clinical and device performance indicators: Operational metrics include First Shock Conversion Efficacy (96%) and False Alarm Rate (6%), which can inform confidence in device performance and patient experience.
  • Sustained daily use: Daily Median Rate of Wear Time (23) and Median Daily Use (23.2) suggest patients are using the device consistently after adoption.

Bear case

  • Very negative operating profitability: The latest period shows an operating margin of -141.6%, indicating substantial operating cost pressure even with a 52.6% gross margin.
  • Execution risk from funnel conversion: Key operating metrics emphasize conversion and prescription flow, so results may be sensitive to changes in Conversion Rate and related prescribing and fitting effectiveness.
  • Payer and coverage dependence: The Percentage of Fittings with In-Network Benefits (80%) implies performance depends in part on payer coverage and in-network access, which can vary over time.
  • Performance and patient experience variability: Device and experience metrics like False Alarm Rate and wear-time measures can shift due to patient mix, adherence, and care settings, affecting outcomes and operational efficiency.
Valuation — source: SEC EDGAR (first-party)
Price$27.20
Market Cap$1.59B
Price / Book6.14
Price / Sales19.54
FCF Yield-15.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$95.13M
Net Margin-138.4%
Revenue Growth (YoY)59.0%
EPS Growth (YoY)-52.6%
FCF Growth (YoY)16.0%
Financial Health — source: SEC EDGAR
Altman Z-Score6.73 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBain Capital Investors LLC ($501.68M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOBrian Webster
Employees300
CountryUS
IPO Date2025-03-06

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • AtriCure, Inc. (ATRC)
  • LeMaitre Vascular, Inc. (LMAT)
  • Inspire Medical Systems, Inc. (INSP)
  • Tandem Diabetes Care, Inc. (TNDM)
  • Alphatec Holdings, Inc. (ATEC)
  • Artivion, Inc. (AORT)
  • Integra LifeSciences Holdings Corporation (IART)
  • PROCEPT BioRobotics Corporation (PRCT)
KMTS earnings history · KMTS institutional & insider holders · KMTS KPIs & operating metrics · KMTS financials · KMTS investor presentations & press releases · KMTS SEC filings · KMTS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.